World Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Wellness Times.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on October 18, 2025

October 18, 2025

Nirvana Recovery’s Integrated Model Leads Arizona’s Alcohol Fight

EIN Presswire

October 18, 2025

Noah Coughlan embarks on Historic Trek to Cross All 50 States on Foot with only 14 States Remaining

EIN Presswire

October 18, 2025

New Book: Experiencing Transcendence Reimagines Addiction & Trauma Recovery Moving Beyond Lifelong Struggle to Freedom

EIN Presswire

October 18, 2025

Free Welcome Bonus No Deposit Required Real Money Online Casino By Cafe Casino

GlobeNewswire

October 18, 2025

Free Spins No Deposit Bonus Casino Canada By Cafe Casino

GlobeNewswire

October 18, 2025

Crypto Casino No Deposit Bonus | Bitcoin Casino No Deposit Bonus 2025 By Cafe Casino

GlobeNewswire

October 18, 2025

Free Spins No Deposit UK | Real Money Online Casino In UK By Cafe Casino

GlobeNewswire

October 18, 2025

Herpafend Addresses Herpes Outbreak Prevention as Natural Remedies Market Reaches $1.23 Billion

GlobeNewswire

October 18, 2025

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

GlobeNewswire

October 18, 2025

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

GlobeNewswire

October 18, 2025

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

GlobeNewswire

October 18, 2025

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

GlobeNewswire

October 18, 2025

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

GlobeNewswire

October 18, 2025

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

GlobeNewswire

October 18, 2025

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

GlobeNewswire

October 18, 2025

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

GlobeNewswire

October 18, 2025

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

GlobeNewswire

October 18, 2025

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

GlobeNewswire

October 18, 2025

General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025

GlobeNewswire

October 18, 2025

rYojbaba Expands Core Consulting and Health Services Business Internationally Through Partnerships with Koyamada International Foundation and Guardian Girls International

GlobeNewswire